Brooklyn Total Debt Trend from 2010 to 2022

BTX
 Stock
  

USD 0.57  0.03  5.00%   

Brooklyn Immunotherapeuti Total Debt yearly trend continues to be fairly stable with very little volatility. Total Debt is likely to outpace its year average in 2022. During the period from 2010 to 2022, Brooklyn Immunotherapeuti Total Debt regression line of anual values had slope of 274,228 and arithmetic mean of  3,775,789. Brooklyn Immunotherapeuti Direct Expenses is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Direct Expenses of 442,750 in 2021. Cost of Revenue is likely to rise to about 9.2 M in 2022, whereas Consolidated Income is likely to drop (125.5 M) in 2022.
  
Refresh
Check Brooklyn Immunotherapeuti financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Brooklyn main balance sheet or income statement drivers, such as Direct Expenses of 541.5 K, Cost of Revenue of 9.2 M or Gross Profit of 12.2 M, as well as many exotic indicators such as Long Term Debt to Equity of 3.0E-4, PPandE Turnover of 1.03 or Receivables Turnover of 11.02. Brooklyn financial statements analysis is a perfect complement when working with Brooklyn Immunotherapeuti Valuation or Volatility modules. It can also supplement various Brooklyn Immunotherapeuti Technical models. Continue to the analysis of Brooklyn Immunotherapeuti Correlation against competitors.

Brooklyn Immunotherapeuti Quarterly Total Debt

2.72 Million

Share

Brooklyn Total Debt Breakdown

Showing smoothed Total Debt of Brooklyn Immunotherapeutics with missing and latest data points interpolated. Total Debt of Brooklyn Immunotherapeuti is a combination of both Brooklyn Immunotherapeuti short-term and long-term liabilities. Short-term debts are those that must be paid back within a year. This type of debt applies to things like lines of credit or short-term term bonds. Long-term debt of Brooklyn Immunotherapeutics includes liability that must be paid off in more than a year. This typically includes large senior debts like mortgages, bonds, as well as business loans or leases. A component of Total Liabilities representing the total amount of current and non-current debt owed. Includes secured and unsecured bonds issued; commercial paper; notes payable; credit facilities; lines of credit; capital lease obligations; operating lease obligations; and convertible notes.Brooklyn Immunotherapeuti's Total Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Brooklyn Immunotherapeuti's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 2.72 M10 Years Trend
Increasing
Slightly volatile
 Total Debt 
Share
      Timeline 

Brooklyn Total Debt Regression Statistics

Arithmetic Mean 3,775,789
Geometric Mean 2,435,258
Coefficient Of Variation 72.15
Mean Deviation 2,187,806
Median 3,793,263
Standard Deviation 2,724,339
Range 8,288,000
R-Value 0.39
R-Squared 0.15
Significance 0.19
Slope 274,228

Brooklyn Total Debt History

2012237 K
20131.7 M
20145.4 M
20157.7 M
20168.5 M
20175.4 M
20183.8 M
20196.1 M
20202.9 M
20212.7 M
20223.8 M

Other Fundumenentals of Brooklyn Immunotherapeuti

Brooklyn Immunotherapeuti Total Debt component correlations

About Brooklyn Immunotherapeuti Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Brooklyn Immunotherapeuti income statement, its balance sheet, and the statement of cash flows. Brooklyn Immunotherapeuti investors use historical funamental indicators, such as Brooklyn Immunotherapeuti's Total Debt, to determine how well the company is positioned to perform in the future. Although Brooklyn Immunotherapeuti investors may use each financial statement separately, they are all related. The changes in Brooklyn Immunotherapeuti's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Brooklyn Immunotherapeuti's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Brooklyn Immunotherapeuti Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Brooklyn Immunotherapeuti. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Total Debt2.7 M3.8 M
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Brooklyn Immunotherapeuti operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 10 people.

Brooklyn Immunotherapeuti Investors Sentiment

The influence of Brooklyn Immunotherapeuti's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Brooklyn. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Brooklyn Immunotherapeuti Implied Volatility

    
  0.0  
Brooklyn Immunotherapeuti's implied volatility exposes the market's sentiment of Brooklyn Immunotherapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Brooklyn Immunotherapeuti's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Brooklyn Immunotherapeuti stock will not fluctuate a lot when Brooklyn Immunotherapeuti's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Brooklyn Immunotherapeuti in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Brooklyn Immunotherapeuti's short interest history, or implied volatility extrapolated from Brooklyn Immunotherapeuti options trading.

Current Sentiment - BTX

Brooklyn Immunotherapeuti Investor Sentiment

Greater number of Macroaxis users are currently bullish on Brooklyn Immunotherapeutics. What is your opinion about investing in Brooklyn Immunotherapeutics? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Continue to the analysis of Brooklyn Immunotherapeuti Correlation against competitors. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
33 M
Return On Assets
-0.74
Return On Equity
-156.16
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.